KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

M J Naughton, D M Zahrieh, M Gnant, N Zdenkowski, J Lemieux, J J Mao, V Bjelic-Radisic, E Shinn, M Balic, C Thomssen, J L Meisel, G M Ruiz, S Loibl, C Isaacs, D Cameron, F M Henao-Carrasco, M P Goetz, C F Singer, G Werutsky, H S Rugo, M Vetter, L-M Tseng, K Miller, F Fitzal, J M Gil Gil, H Park, B Linderholm, E Bajetta, Z Dayao, A Prat, K Ehrhardt, O Metzger, A Arahmani, E H Law, A H Partridge, L A Carey, A Zoroufy, A C Dueck, P O'Brien, D Hlauschek, A DeMichele, E L Mayer

ESMO Open 10(6) 105120

PMID40472660
PMCIDPMC12173008
DOI10.1016/j.esmoop.2025.105120
发表日期2025-06-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。
摘要

摘要

BACKGROUND: The PALLAS phase III, randomized trial investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) improved invasive disease-free survival (iDFS) over adjuvant ET alone. This study reports the patient-reported outcomes (PROs) by treatment arm. PATIENTS AND METHODS: A total of 4688 of 5796 PALLAS patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II-III breast cancer completed PRO measures. Patients were randomly assigned (1 : 1) to either 2 years of palbociclib (125 mg/day, 3 weeks on 1 week off) plus ongoing provider or patient-choice adjuvant ET (palbociclib + ET) versus ongoing ET alone. Eight PRO endpoints were measured serially (i.e. day 1 of each monthly cycle for the first 3 months, then every 3 months for 2 years, and once at 3 years). These endpoints were the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/quality-of-life (QoL) score, the Brief Fatigue Inventory (BFI) score, the modified Brief Pain Inventory (mBFI) severity and pain interference scores, the EORTC Core Quality of Life Questionaire-Breast 23 (QLQ-BR23) alopecia score, and the Breast Cancer Prevention Trial (BCPT) hot flash symptoms, vaginal problems, and musculoskeletal pain scores. Treatment with palbociclib stopped after the second interim analysis (May 2020) due to futility, and patients transitioned to follow-up. RESULTS: After adjustment for baseline covariates, on average, no significant differences between arms were observed on any of the eight endpoints over the study period. However, there were differences by treatment regimen in the worsening of symptoms over time, and by race and ethnicity. These findings have important implications for the management of symptoms in HR-positive/HER2-negative breast cancer survivors receiving endocrine and/or other therapies long term. CONCLUSIONS: No clinically significant differences in patient-reported QoL or symptom severity were found by treatment arm. However, the results of the PRO analyses may inform patient-centered communication and adherence efforts regarding treatment toxicity in subgroups of survivors.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1CONSORT diagram. CONSORT diagram of the PALLAS Trial Patient Screening and Randomization.
非 KM Figure
Figure 2Graphs of patient average group differences for the EORTC-QLQ-C30 Global Health Status Score and the Brief Pain Inventory Severity Score Over the Trial Period. The adjusted score for the EORTC QLQ-C30 global health status/QoL score by study arm over the cycle period and the adjusted BPI severity score by study arm over the cycle period are shown.BPI, Brief Pain Inventory; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life. a Although the test of interaction between treatment arm and time achieved statistical significance, the pattern of change in the mean scores for both the EORTC QLQ-C30 global health/QoL and the BPI pain severity items was not clinically significantly different (i.e. both P values for the interaction effects were P < 0.0001).
非 KM Figure
Figure 3Time to w ors ening among the PALLAS PRO variables. (A-H) Cumulative incidence of worsening PRO scores and time from first PRO assessment in months for EORTC QLQ-C30 global health status (A), Brief Fatigue Inventory scores (B), modified Brief Pain Inventory severity scores (C), modified Brief Pain Inventory interference scores (D), EORTC QLQ-BR23 alopecia scores (E), BCPT hot flash scores (F), BCPT vaginal problems scores (G), and BCPT musculoskeletal pain scores (H). BCPT, Breast Cancer Prevention Trial; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; PRO, patient-reported outcome.
非 KM Figure